Last reviewed · How we verify
NCT03595891
The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung
trial testing Non-Interventional in Pulmonary Embolism (PE) in 660 participants. Completed in 29 January 2021.
29 January 2021
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 660 |
| Start date | 20 January 2017 |
| Primary completion | 29 January 2021 |
| Estimated completion | 29 January 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Non-Interventional
Conditions studied
- Pulmonary Embolism (PE) — all drugs for Pulmonary Embolism (PE) →
- Pulmonary Thromboembolism — all drugs for Pulmonary Thromboembolism →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Pulmonary Embolism (PE) or Pulmonary Thromboembolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study based on a chart review of participants that presented with a sudden blood clot in the lung
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03595891
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional
Trials testing the same drug.
- NCT06412029 — Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices · enrolling by invitation
- NCT05568459 — A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standa · active not recruiting
- NCT06527508 — Construct Validity and Intra-Observer Reliability of the SDQ · completed
- NCT05919511 — Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease · recruiting
- NCT05510908 — Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · completed
Other recruiting trials for Pulmonary Embolism (PE)
Currently open trials in the same condition.
- NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
- NCT06946732 — Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism · NA · recruiting
- NCT07452991 — ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE · NA · recruiting
- NCT06596941 — Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis · active not recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03595891 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 5 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03595891.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing